1-20 of 54
Lindsey E. Roeker
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial

Clinical Trials & Observations
Lindsey E. Roeker, Jennifer A. Woyach, Chan Y. Cheah, Catherine C. Coombs, Nirav N. Shah, William G. Wierda, Manish R. Patel, Nicole Lamanna, Donald E. Tsai, Binoj Nair, Chunxiao Wang, Xiang Zhao, Dan Liu, David Radtke, Sonya Chapman, Narasimha Marella, Samuel C. McNeely, Jennifer R. Brown
Journal: Blood
Blood (2024) 144 (13): 1374–1386.
https://doi.org/10.1182/blood.2024024510
Published: 2024
Includes: Supplemental data
Journal Articles

A fresh look at covalent BTK inhibitor resistance

Clinical Trials & Observations
Lindsey E. Roeker
Journal: Blood
Blood (2024) 144 (10): 1029–1031.
https://doi.org/10.1182/blood.2024025237
Published: 2024
Journal Articles

A Phase 1a/b Trial of Luxeptinib (CG-806) in Patients with Relapsed/Refractory B-Cell Malignancies or Acute Myeloid Leukemia and Evaluation of New G3 Formulation

Aaron D. Goldberg, Felipe Samaniego, Maro Ohanian, Paul B. Koller, Namrata Sonia Chandhok, Ahad A. Sadiq, Daruka Mahadevan, Mohamad A. Cherry, Jessica K. Altman, John M. Burke, Michael Z. Koontz, J. C. C Villasboas, Ben K. Tomlinson, Laura E. Finn, Erin G Reid, Jason Melear, Victor Priego, Patrick Cobb, Elizabeth Heritage Cull, Paul Conkling, David Cosgrove, Lindsey E. Roeker, Eric Tam, Donna Nguyen Haney, Jia Hu, Ranjeet Sinha, Nawazish Khan, William G. Rice, Rafael Bejar
Journal: Blood
Blood (2023) 142 (Supplement 1): 5953.
https://doi.org/10.1182/blood-2023-181151
Published: 2023
Journal Articles

Pirtobrutinib in Post-cBTKi CLL/SLL: ~30 Months Follow-up and Subgroup Analysis With/Without Prior BCL2i from the Phase 1/2 BRUIN Study

Jennifer A. Woyach, Jennifer R. Brown, Paolo Ghia, Lindsey E. Roeker, Krish Patel, Toby A. Eyre, Talha Munir, Ewa Lech-Maranda, Nicole Lamanna, Constantine S. Tam, John F. Seymour, Benoit Tessoulin, Nirav N. Shah, Chaitra S Ujjani, Bita Fakhri, Catherine C. Coombs, Ian W. Flinn, Manish Patel, Sunita D. Nasta, Jonathon B. Cohen, Alvaro J. Alencar, Chan Y. Cheah, Shuo Ma, Joanna M. Rhodes, Deepa Jagadeesh, Pier Luigi Zinzani, Anders Osterborg, Koji Izutsu, Donald E. Tsai, Paolo Abada, Minna Balbas, Jian Li, Amy S. Ruppert, Wojciech Jurczak, William G. Wierda
Journal: Blood
Blood (2023) 142 (Supplement 1): 325.
https://doi.org/10.1182/blood-2023-185852
Published: 2023
Journal Articles

Despite High Rates of Remission, Treatment of IDH-Mutant AML with Hypomethylating Agents and Venetoclax Is Associated with Frequent Treatment Delays, Modifications, and Transfusions

Kuo-Kai Chin, Andriy Derkach, Christopher Famulare, Gaurav Gupta, Prabhakar Borge, Ellin Berman, Mark Blaine Geyer, Aaron D. Goldberg, Tamanna Haque, Raajit K. Rampal, Jae H. Park, Lindsey E. Roeker, Martin S. Tallman, Eytan M. Stein
Journal: Blood
Blood (2023) 142 (Supplement 1): 1519.
https://doi.org/10.1182/blood-2023-182012
Published: 2023
Journal Articles

Pirtobrutinib in Richter Transformation: Updated Efficacy and Safety Results with 18-Month Median Survival Follow-up from the Phase 1/2 BRUIN Study

William G. Wierda, Nirav N. Shah, Chan Yoon Cheah, David Lewis, Marc S. Hoffmann, Catherine C. Coombs, Nicole Lamanna, Shuo Ma, Deepa Jagadeesh, Talha Munir, Yucai Wang, Toby A. Eyre, Joanna M. Rhodes, Matthew McKinney, Ewa Lech-Maranda, Constantine S. Tam, Wojciech Jurczak, Koji Izutsu, Alvaro J. Alencar, Manish Patel, John F. Seymour, Jennifer A. Woyach, Lindsey E. Roeker, Philip A. Thompson, Paolo Abada, Caleb Ho, Narasimha Marella, Chunxiao Wang, Amy S. Ruppert, Binoj Chandrasekharan Nair, Hui Liu, Donald E. Tsai, Paolo Ghia
Journal: Blood
Blood (2023) 142 (Supplement 1): 1737.
https://doi.org/10.1182/blood-2023-181108
Published: 2023
Journal Articles

Treatment Effectiveness with Venetoclax-Based Therapy after Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study

Nilanjan Ghosh, Nicole Lamanna, Toby A. Eyre, Catherine C Coombs, Beenish S Manzoor, Jennifer R. Brown, Hande H. Tuncer, Chaitra S Ujjani, Lori A Leslie, Lindsey E. Roeker, Matthew S Davids, Joanna M. Rhodes, Alan Skarbnik, Nnadozie Emechebe, Isabelle Fleury, Brian T. Hill, Christopher P. Fox, Paul M. Barr, Dureshahwar Jawaid, Wendy J Sinai, Laurie K Pearson, Frederick Lansigan, Yun Choi, Christopher E. Jensen, Stephen J. Schuster, Kaitlin Kennard, Irina Pivneva, Talissa Watson, Annie Guerin, Mazyar Shadman
Journal: Blood
Blood (2023) 142 (Supplement 1): 1908.
https://doi.org/10.1182/blood-2023-179198
Published: 2023
Journal Articles

Fixed-Duration Pirtobrutinib Combined with Venetoclax ± Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Results, Including MRD Data, from the BRUIN Phase 1b Study

Lindsey E. Roeker, Jennifer A. Woyach, Chan Y. Cheah, Catherine C Coombs, Nirav N. Shah, William G. Wierda, Manish Patel, Donald E. Tsai, Binoj Nair, Chunxiao Wang, Xiang Zhao, Narasimha Marella, Caleb Ho, Samuel McNeely, Jennifer R. Brown
Journal: Blood
Blood (2023) 142 (Supplement 1): 3269.
https://doi.org/10.1182/blood-2023-181090
Published: 2023
Journal Articles

Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) Patients with Prior cBTKi: Safety and Efficacy Including High-Risk Subgroup Analyses from the Phase 1/2 BRUIN Study

Jonathon B. Cohen, Nirav N. Shah, Wojciech Jurczak, Pier Luigi Zinzani, Chan Y. Cheah, Toby A. Eyre, Chaitra S Ujjani, Youngil Koh, Won Seog Kim, Sunita D. Nasta, Ian W. Flinn, Benoit Tessoulin, Shuo Ma, Alvaro J. Alencar, David Lewis, Jennifer A. Woyach, Kami J. Maddocks, Krish Patel, Yucai Wang, Joanna M. Rhodes, Constantine S. Tam, John F. Seymour, Hirokazu Nagai, Julie M. Vose, Bita Fakhri, Marc S. Hoffmann, Francisco J. Hernandez-Ilizaliturri, Andrew D. Zelenetz, Anita Kumar, Talha Munir, Donald E. Tsai, Minna Balbas, Bin Liu, Amy S. Ruppert, Bastien Nguyen, Lindsey E. Roeker, Michael L. Wang
Journal: Blood
Blood (2023) 142 (Supplement 1): 981.
https://doi.org/10.1182/blood-2023-181627
Published: 2023
Journal Articles

Outcomes of Patients with Richter Transformation without Prior Chemoimmunotherapy for CLL/SLL: An International Multicenter Retrospective Study

Adam S Kittai, Ying Huang, Sarah Miller, John N. Allan, Seema A Bhat, David A. Bond, Danielle M Brander, John C. Byrd, Julio C Chavez, Elise A. Chong, Matthew S Davids, Alexey Danilov, Wei Ding, Mark R Dowling, Kaitlyn M. Dvorak-Kornaus, Hannah Freedman, Paul J Hampel, Carrie I Ho, Steven R Hwang, Prioty Islam, Nitin Jain, Matthew Matasar, Cecelia Miller, Erin M Parry, Kari G. Rabe, Manoj Rai, Phil Raess, Lindsey E. Roeker, Joanna M. Rhodes, Kerry A Rogers, Aditi Saha, Jake Schade, Hamish S Scott, Mazyar Shadman, Geoffrey P. Shouse, Alan Skarbnik, Stephen E Spurgeon, Deborah M. Stephens, Meghan C. Thompson, Philip A. Thompson, Yucai Wang, William G. Wierda, Max Yano, Omer Zulfa, Jennifer A. Woyach
Journal: Blood
Blood (2023) 142 (Supplement 1): 497.
https://doi.org/10.1182/blood-2023-182114
Published: 2023
Journal Articles

A Phase 2 Study of Minimal Residual Disease (MRD)-Adapted Front Line Venetoclax and Obinutuzumab in Fit Patients with Chronic Lymphocytic Leukemia (CLL): Effect of Obinutuzumab on Tumor Lysis Syndrome (TLS) Risk and Safety of Outpatient Venetoclax Dose Escalation

Lindsey E. Roeker, Andrew D. Zelenetz, Jae H. Park, Andriy Derkach, Mark Blaine Geyer, Prioty Islam, Lorenzo Falchi, Maria Lia Palomba, Anita Kumar, Gilles Salles, Jennifer Kimberly Lue, Aaron D. Goldberg, Bita Fakhri, Catherine C. Coombs, Victoria Falco, Gail Panton, Dianna Tyznar, Dhara Soni, Lauren Nogan, Sonia Lebowitz, Katherine Blesie, Monica Shah, Sarah Court, Christopher E. Jensen, Anthony R. Mato, Meghan C. Thompson
Journal: Blood
Blood (2023) 142 (Supplement 1): 4657.
https://doi.org/10.1182/blood-2023-181661
Published: 2023
Journal Articles

Genomic Evolution and Resistance during Pirtobrutinib Therapy in Covalent BTK-Inhibitor (cBTKi) Pre-Treated Chronic Lymphocytic Leukemia Patients: Updated Analysis from the BRUIN Study

Jennifer R. Brown, Sai Prasad Desikan, Bastien Nguyen, Helen Won, Shady I. Tantawy, Samuel McNeely, Narasimha Marella, Kevin Ebata, Jennifer A. Woyach, Krish Patel, Constantine S. Tam, Toby A. Eyre, Chan Y. Cheah, Nirav N. Shah, Paolo Ghia, Wojciech Jurczak, Minna Balbas, Binoj Nair, Paolo Abada, Chunxiao Wang, Ying (Denise) Wang, Lindsey E. Roeker, Varsha Gandhi, William G. Wierda
Journal: Blood
Blood (2023) 142 (Supplement 1): 326.
https://doi.org/10.1182/blood-2023-180143
Published: 2023
Journal Articles

Patient-Reported Outcomes (PROs) Among Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Receiving Pirtobrutinib: Analysis from the BRUIN Phase 1/2 Study

Catherine C. Coombs, Jennifer A. Woyach, Jennifer R. Brown, Paolo Ghia, Lindsey E. Roeker, Krish Patel, Toby A. Eyre, Constantine S. Tam, John F. Seymour, Nirav N. Shah, Ian W. Flinn, Chan Y. Cheah, Shuo Ma, Joanna M. Rhodes, Koji Izutsu, Wojciech Jurczak, William G. Wierda, Angely Loubert, Nalin Payakachat, Lisa M. Hess, Paolo Abada, Nicole Lamanna
Journal: Blood
Blood (2023) 142 (Supplement 1): 6535.
https://doi.org/10.1182/blood-2023-186145
Published: 2023
Journal Articles

NX-2127-001, a First-in-Human Trial of NX-2127, a Bruton's Tyrosine Kinase-Targeted Protein Degrader, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and B-Cell Malignancies

Anthony R. Mato, William G. Wierda, Weiyun Z. Ai, Ian W. Flinn, Michael Tees, Manish R. Patel, Krish Patel, Susan O'Brien, David A. Bond, Lindsey E. Roeker, Tanya Siddiqi, Michael L. Wang, Clare Sun, Omar Abdel-Wahab, Amanda Schwab, May Tan, Erin Meredith, Melissa A. Gessner, Su Young Kim, Adrian Wiestner, Alexey V Danilov
Journal: Blood
Blood (2022) 140 (Supplement 1): 2329–2332.
https://doi.org/10.1182/blood-2022-164772
Published: 2022
Journal Articles

Real World Comparison of Bruton Tyrosine Kinase Inhibitors and Venetoclax in Patients Diagnosed with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Lindsey E. Roeker, Yi Han, Kellie J. Ryan, Anna Teschemaker, Anthony R. Mato
Journal: Blood
Blood (2022) 140 (Supplement 1): 7025–7027.
https://doi.org/10.1182/blood-2022-163534
Published: 2022
Journal Articles

A Phase 1a/b Dose Escalation Study of the BTK/FLT3 Inhibitor Luxeptinib in Patients with Relapsed or Refractory B-Cell Malignancies

Felipe Samaniego, Ahad A. Sadiq, Daruka Mahadevan, Michael Z. Koontz, Jose C. Villasboas, John M. Burke, Erin G Reid, Mohamad Cherry, Jason Melear, Victor Priego, Patrick Cobb, Elizabeth H. Cull, Paul Conkling, David Cosgrove, Lindsey E. Roeker, Donna Nguyen Haney, Jia Hu, Ranjeet Kumar Sinha, William G Rice, Rafael Bejar
Journal: Blood
Blood (2022) 140 (Supplement 1): 6498–6500.
https://doi.org/10.1182/blood-2022-163683
Published: 2022
Journal Articles

Kinase Dead BTK Mutations Confer Resistance to Covalent and Noncovalent BTK Inhibitors but Are Susceptible to Clinical Stage BTK Degraders

Skye Montoya, Jessie Bourcier, Meghan C. Thompson, Mark Noviski, May Tan, Eric Wang, Xiaoli Mi, Nivetha Brathaban, Carla Barrientos Risso, Daniel Tsai, Jordan Ye, Jacob Jahn, Gabriel Pardo, Lee Cabuhat, Ryan Notti, Alejandro Pardo, Maurizio Affer, Stephanie Yung, James Luliano, Janine Powers, Daniel W Robbins, Vindhya Nawaratne, Tulasigeri M Totiger, Camila Pena-Velasquez, Joanna M. Rhodes, Andrew D. Zelenetz, Lindsey E. Roeker, Hao Lu, Adam Linley, Anthony R. Mato, Omar Abdel-Wahab, Justin Taylor
Journal: Blood
Blood (2022) 140 (Supplement 1): 1811–1813.
https://doi.org/10.1182/blood-2022-163268
Published: 2022
Journal Articles

Outcomes of Therapies and Resistance Mutations Following Non-Covalent Bruton's Tyrosine Kinase Inhibitor Treatment for Patients with Chronic Lymphocytic Leukemia and Richter Transformation

Meghan C. Thompson, Catherine C. Coombs, Lindsey E. Roeker, Jeffrey L. Jensen, Nirav N. Shah, Thomas Luo, Krish Patel, Neil Bailey, Bita Fakhri, Toby A. Eyre, Paola Ghione, Joanna M. Rhodes, Andrew D. Zelenetz, Justin Taylor, Maria Lia Palomba, Kendall Meyer, Danielle Rao, Yehudit Fox, Julia H. Aronson, Sarah Court, Omar Abdel-Wahab, Anthony R. Mato
Journal: Blood
Blood (2022) 140 (Supplement 1): 9885–9888.
https://doi.org/10.1182/blood-2022-159133
Published: 2022
Journal Articles

Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN Study

William G. Wierda, David John Lewis, Paolo Ghia, Nirav N. Shah, Catherine C. Coombs, Chan Y. Cheah, Nicole Lamanna, Joanna M. Rhodes, Marc Hoffmann, Shuo Ma, Toby A. Eyre, Talha Munir, Manish R. Patel, Alvaro J. Alencar, Constantine S. Tam, John F. Seymour, Wojciech Jurczak, Ewa Lech-Marańda, Lindsey E. Roeker, Philip A. Thompson, Paolo B. Abada, Chunxiao Wang, Binoj Nair, Hui Liu, Donald E. Tsai, Anthony R. Mato
Journal: Blood
Blood (2022) 140 (Supplement 1): 846–849.
https://doi.org/10.1182/blood-2022-157058
Published: 2022
Journal Articles

Comparing Acalabrutinib and Ibrutinib in the Real World: A Study of 2,509 Patients with Chronic Lymphocytic Leukemia

Lindsey E. Roeker, Maral DerSarkissian, Kellie J. Ryan, Yan Chen, Svea K. Wahlstrom, Shweta Hakre, Louise Yu, Helen Guo, Anthony R. Mato
Journal: Blood
Blood (2022) 140 (Supplement 1): 4156–4158.
https://doi.org/10.1182/blood-2022-167213
Published: 2022